<DOC>
	<DOCNO>NCT02102243</DOCNO>
	<brief_summary>Patients high aldosterone hormone high blood glucose normal people . This study do understand aldosterone hormone affect nerve activity control blood flow muscle blood glucose . The information may helpful select blood pressure medication improve blood pressure also improve blood sugar .</brief_summary>
	<brief_title>Neural Mechanism Aldosterone-induced Insulin Resistance</brief_title>
	<detailed_description>Patients primary aldosteronism know impaired insulin sensitivity , improve removal aldosterone-producing adenoma . In patient essential hypertension , plasma aldosterone level also show positively correlate index insulin resistance . Mechanism underlie aldosterone-induced insulin resistance unknown . Aldosterone show interfere insulin signal vascular cell increase production reactive oxygen specie via activation NADPH oxidase , result decreased availability nitric oxide ( NO ) , key mediator insulin-mediated vasodilation . Treatment mineralocorticoid receptor antagonist show improve insulin sensitivity mouse obesity metabolic syndrome . Aldosterone also show increase rest sympathetic vasoconstrictor activity peripheral circulation . However , effect aldosterone mineralocorticoid receptor antagonists insulin-mediated skeletal muscle vasodilation , sympathetic activation , vascular oxidative stress assess human . The investigator collect venous endothelial cell , measure skeletal muscle microvascular perfusion use Octafluoropropane microbubble contrast agent , measure sympathetic nerve activity normotensive control ( NT ) , stage 1 essential hypertensive subject ( ET ) , patient primary aldosteronism ( PA ) hyperinsulinemic euglycemic clamp .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Normotensive control 2 . Stage I ( 140159/9099 mmHg ) untreated subject essential hypertension 3 . Patients PA stage I ( 140159/9099 mmHg ) hypertension 1 . Congestive heart failure coronary artery disease 2 . Blood pressure average &gt; 159/99 mmHg 3 . Serum creatinine &gt; 1.5 mg/dL 4 . Diabetes mellitus systemic illness 5 . Left ventricular hypertrophy echocardiography ECG 6 . Pregnancy 7 . Hypersensitivity spironolactone , chlorthalidone , amlodipine , human recombinant insulin Definity 8 . Any history substance abuse ( tobacco ) 9 . History gouty arthritis 10 . Patients righttoleft , bidirectional , transient righttoleft cardiac shunt 11 . Hypersensitivity perflutren , blood , blood product albumin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>sympathetic nerve activity</keyword>
	<keyword>vascular oxidative stress</keyword>
	<keyword>nitric oxide</keyword>
	<keyword>nitric oxide synthase ( eNOS )</keyword>
	<keyword>endothelium</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>endothelial cell protein expression</keyword>
	<keyword>microvascular blood flow</keyword>
	<keyword>flow mediate dilation</keyword>
	<keyword>endothelial cell collection</keyword>
	<keyword>microbubbles</keyword>
	<keyword>Definity</keyword>
</DOC>